Corixa Corporation

ANERGIX

(Based on Intent to Use) Biopharmaceutical compounds used in the treatment of autoimmune diseases;

CORIXA

research in the field of genetics, genomics, molecular biology and immunology;

CORIXA

research in the field of genetics, genomics, molecular biology and immunology;The stippling in the drawing indicates shading, and does not indicate color.;

CORIXA

vaccines and pharmaceuticals for the treatment of cancer, infectious diseases, viral diseases and automimmune disorders, and medical diagnostic preparations, for human and veterinary use;

CORIXA

vaccines and pharmaceuticals for the treatment of cancer, infectious diseases, viral diseases and autoimmune disorders, and medical diagnostic preparations, for human and veterinary use;The stippling in the drawing indicates shading, and does not indicate color.;

CORIXA

In the statement, column 1, lines 1 through 4, should be deleted, and, Corixa Corporation (Delaware Corporation), 1124 Columbia Street, Suite 464, Seattle, WA 98104 should be inserted. In the statement, column 2, line 2, tal should be deleted, and, ral should be inserted. In the statement, Column 2, line 2, automimmune should be deleted, and, autoimmune should be inserted.;vaccines and pharmaceuticals for the treatment of cancer, infectious diseases, [ vital ] * viral * diseases and [ automimmune ] * autoimmune * disorders, and medical diagnostic preparations, for human and veterinary use;

DUAL ACTION, DURABLE REMISSION

pharmaceuticals for the treatment of cancer;DUAL ACTION DURABLE REMISSION;

DUAL ACTION, DURABLE REMISSION

printed educational materials, namely pamphlets, booklets and brochures concerning non-Hodgkin's lymphoma and treatments therefore;DUAL ACTION DURABLE REMISSION;

EXXCEPTIONAL EFFICACY

pharmaceuticals for the treatment of cancer;EXCEPTIONAL EFFICACY;

EXXCEPTIONAL EFFICACY

Printed educational materials, namely pamphlets, booklets and brochures concerning non-Hodgkin's lymphoma and treatments therefore;EXCEPTIONAL EFFICACY;

MELACINE

pharmaceutical preparations, namely, vaccines for the treatment of malignant melanoma in humans;

MPL

pharmaceutical preparations; namely, immunostimulants for the prevention and treatment of infectious and noninfectious diseases in humans and in livestock, pets, and laboratory animals; and for use as medical laboratory reagents;

POWERED BY CORIXA

VACCINES, PHARMACEUTICALS AND THERAPEUTIC CHEMICAL COMPOSITIONS FOR THE TREATMENT OF CANCER, INFECTIOUS DISEASES, VIRAL DISEASES, AND AUTOIMMUNE DISORDERS; MEDICAL DIAGNOSTIC PREPARATIONS; IMMUNOSTIMULANTS; AND VACCINE ADJUVANTS, ALL FOR HUMAN AND VETERINARY USE;The stippling in the drawing indicates shading and does not indicate color;

TARGETED PRECISE DURABLE

Pharmaceuticals for the treatment of cancer;

TARGETED PRECISE DURABLE

Printed educational materials, namely pamphlets, booklets and brochures concerning non-Hodgkin's lymphoma and treatments therefore;

XABREX

pharmaceuticals for the treatment of cancer;